bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Here’s Why

bioMerieux (OTCMKTS:BMXMF) gapped up before the market opened on Tuesday . The stock had previously closed at $83.17, but opened at $88.4950. bioMerieux shares last traded at $88.4950, with a volume of 106 shares.

Analyst Ratings Changes

Several research analysts have recently weighed in on BMXMF shares. Piper Sandler assumed coverage on shares of bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating for the company. UBS Group cut shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Zacks Research downgraded shares of bioMerieux from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

bioMerieux Stock Up 6.4%

The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average of $79.87 and a 200 day moving average of $93.15.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.